- Home
- DHT vs CDTX Comparison
DHT vs CDTX Comparison
Compare DHT & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHT
- CDTX
- Stock Information
- Founded
- DHT 2005
- CDTX 2012
- Country
- DHT Bermuda
- CDTX United States
- Employees
- DHT N/A
- CDTX N/A
- Industry
- DHT Marine Transportation
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHT Consumer Discretionary
- CDTX Health Care
- Exchange
- DHT Nasdaq
- CDTX Nasdaq
- Market Cap
- DHT 1.7B
- CDTX 1.6B
- IPO Year
- DHT 2005
- CDTX 2015
- Fundamental
- Price
- DHT $11.49
- CDTX $98.51
- Analyst Decision
- DHT Strong Buy
- CDTX Strong Buy
- Analyst Count
- DHT 4
- CDTX 11
- Target Price
- DHT $13.75
- CDTX $91.60
- AVG Volume (30 Days)
- DHT 1.7M
- CDTX 1.2M
- Earning Date
- DHT 11-11-2025
- CDTX 11-06-2025
- Dividend Yield
- DHT 8.29%
- CDTX N/A
- EPS Growth
- DHT 19.95
- CDTX N/A
- EPS
- DHT 1.17
- CDTX N/A
- Revenue
- DHT $557,643,000.00
- CDTX N/A
- Revenue This Year
- DHT N/A
- CDTX N/A
- Revenue Next Year
- DHT $32.35
- CDTX N/A
- P/E Ratio
- DHT $9.79
- CDTX N/A
- Revenue Growth
- DHT N/A
- CDTX N/A
- 52 Week Low
- DHT $8.67
- CDTX $10.14
- 52 Week High
- DHT $13.06
- CDTX $106.63
- Technical
- Relative Strength Index (RSI)
- DHT 40.09
- CDTX 73.40
- Support Level
- DHT $11.27
- CDTX $96.35
- Resistance Level
- DHT $11.93
- CDTX $106.63
- Average True Range (ATR)
- DHT 0.25
- CDTX 6.45
- MACD
- DHT -0.15
- CDTX 1.55
- Stochastic Oscillator
- DHT 13.18
- CDTX 86.26
About DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. The group generates revenues from time charter and spot market operations. It operates through integrated management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from the shipping revenues.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.